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Abstract
Objective To determine whether cognitive therapy is effective in
preventing the worsening of emerging psychotic symptoms experienced
by help seeking young people deemed to be at risk for serious conditions
such as schizophrenia.
Design Multisite single blind randomised controlled trial.
Setting Diverse services at five UK sites.
Participants 288 participants aged 14-35 years (mean 20.74, SD 4.34
years) at high risk of psychosis: 144 were assigned to cognitive therapy
plus monitoring of mental state and 144 to monitoring of mental state
only. Participants were followed-up for a minimum of 12 months and a
maximum of 24 months.
Intervention Cognitive therapy (up to 26 (mean 9.1) sessions over six
months) plus monitoring of mental state compared with monitoring of
mental state only.
Main outcome measures Primary outcome was scores on the
comprehensive assessment of at risk mental states (CAARMS), which
provides a dichotomous transition to psychosis score and ordinal scores
for severity of psychotic symptoms and distress. Secondary outcomes
included emotional dysfunction and quality of life.
Results Transition to psychosis based on intention to treat was analysed
using discrete time survival models. Overall, the prevalence of transition
was lower than expected (23/288; 8%), with no significant difference
between the two groups (proportional odds ratio 0.73, 95% confidence
interval 0.32 to 1.68). Changes in severity of symptoms and distress, as
well as secondary outcomes, were analysed using random effects
regression (analysis of covariance) adjusted for site and baseline
symptoms. Distress from psychotic symptoms did not differ (estimated
difference at 12 months −3.00, 95% confidence interval −6.95 to 0.94)
but their severity was significantly reduced in the group assigned to
cognitive therapy (estimated between group effect size at 12 months
−3.67, −6.71 to −0.64, P=0.018).
Conclusions Cognitive therapy plus monitoring did not significantly
reduce transition to psychosis or symptom related distress but reduced
the severity of psychotic symptoms in young people at high risk. Most
participants in both groups improved over time. The results have
important implications for the at risk mental state concept.
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Trial registration Current Controlled Trials ISRCTN56283883.
Introduction
Reliable and valid criteria are available to identify help seeking
people in diverse settings who are at high risk of imminently
developing schizophrenia and related psychoses. Researchers
developed operational criteria to identify three subgroups
possessing an “at risk mental state” for psychosis.1 Two
subgroups specify state risk factors, defined by the presence of
either transient psychotic symptoms, called brief limited
intermittent psychotic symptoms, or attenuated (subclinical)
psychotic symptoms. The other subgroup comprises trait plus
state risk factors, operationally defined by the presence of
diminished functioning plus either a first degree relative with
a history of psychosis or a pre-existing schizotypal personality
disorder. All subgroups are within a specified age range known
to be at greatest risk for the onset of psychosis, and all
participants in studies to date who are in an at risk mental state
have been help seeking, which effectively means this is part of
the criteria.
Effective interventions to prevent or delay this transition are
needed because of the significant personal, social, and financial
costs associated with the development of psychosis. To date six
randomised controlled trials have reported findings on outcomes
associated with antipsychotic drugs, omega-3 polyunsaturated
fatty acids, and psychological interventions; each using similar
operational definitions of at risk mental state. These studies
(table 1⇓) were carried out in Australia,2 3 North America,4 5 the
United Kingdom,6 7 and Austria.8
We have argued9 that cognitive therapy may be well suited to
patients who are in an at risk mental state since its efficacy has
been shown in acute10 and chronic, persistent psychotic
symptoms11 12 as well as in the prevention of relapse13 and
emotional disorders.14 The current multisite, randomised
controlled trial was designed as a definitive test of the hypothesis
that cognitive therapy would prevent transition to psychosis in
a population who were in an at risk mental state, and would
reduce the severity of and distress associated with psychotic
symptoms. We also hypothesised that cognitive therapy would
reduce emotional dysfunction and improve quality of life.
Methods
We carried out a multisite randomised controlled single blind
(rater) trial comparing cognitive therapy plus monitoring of
mental state with monitoring of mental state only (control).
We assessed entry criteria using the comprehensive assessment
of the at risk mental state (CAARMS), which is specifically
designed for the assessment of people in the category of at risk
mental states.15 The entry routes consist of brief limited
intermittent psychotic symptoms, attenuated psychotic
symptoms, or state plus trait factors. All candidates were aged
between 14 and 35 and seeking help for symptoms. Exclusion
criteria were current or previous receipt of antipsychotic drugs,
moderate to severe learning disability, organic impairment, and
insufficient fluency in English. The five sites involved were
Manchester, Birmingham/Worcestershire, Glasgow,
Cambridgeshire, and Norfolk. Participants were predominantly
identified by health professionals working within diverse
agencies within primary and secondary care settings. Table 2⇓
shows the referral sources for the trial participants. Our
ascertainment strategy was to make services familiar with our
entry criteria and to liaise on a regular basis; no systematic
screening of service populations was carried out. Because
participants were required to be help seeking, we also
emphasised the potential benefits of the monitoring alone
condition. We excluded 45 potential participants for not help
seeking (figure⇓); they were referred as being likely to meet
our criteria by a health professional involved in their treatment
as usual, but when consulted about participation in the study
these individuals made it clear that they were not seeking help.
Interventions
Participants were randomised to monitoring of mental state only
(control) or to cognitive therapy plus monitoring of mental state.
Both conditions were in addition to treatment as usual, which
will have been highly variable and dependent on local service
configurations and specific source of referral to the trial. In an
attempt to control for this variation we stratified randomisation
by site.
Monitoring
All participants received treatment as usual plus regular
monitoring (incorporating CAARMS from a research assistant),
which represents an enhancement over routine care since it
aimed to provide warm, empathic, and non-judgmental face to
face contact and supportive listening; signposting to appropriate
local services for unmet needs and crisis management when
required (usually by referral to a local crisis team, early
intervention service, or psychiatric liaison within emergency
departments). Monitoring ensured that all participants had a
general practitioner with whom they were encouraged to stay
in regular contact and a personalised “crisis card,” which
provided contact details for local sources of help in a psychiatric
emergency. Staff involved in monitoring and those delivering
cognitive therapy did not overlap.
Monitoring plus cognitive therapy
In addition to the monitoring component, participants allocated
to the therapy arm of the trial received cognitive therapy based
on our specific cognitive model.16 Sessions were offered on a
weekly basis for up to a maximum of 26 weeks, plus up to four
booster sessions in the subsequent six months. For many
participants, however, it was expected that the duration of
cognitive therapy would be shorter than this, since shared goals
may be reached earlier; in previous cognitive therapy trials based
on our manual, the mean number of sessions was 116 and 12.5
Cognitive therapy requires an individualised, problem oriented
approach and incorporates a process of assessment and
formulation, which is manualised. The specific interventions
depend on individual goals and formulations, but the range of
permissible interventions is described in our manual.17 Key
ingredients of the approach are the development of a problem
and goal list, early formulation (both longitudinal and
maintenance), a focus on normalising psychotic-like experiences,
and an active therapy stance utilising behavioural experiments
and evaluation of appraisals. Fidelity to the treatment protocol
was ensured by regular supervision of the therapists and assessed
by rating recordings of sessions using a revised version of the
cognitive therapy scale18 and the cognitive therapy for at risk
populations adherence scale.19
Staff in the study sites were trained initially, and therapy
supervisionwas provided byweeklymeetings between therapists
and investigators. Cognitive therapy sessions were taped with
the participant’s consent so that participants could be asked to
listen to the tapes as part of their homework and to assist
supervision. During the course of the trial a sample of 80 tapes
was rated according to the cognitive therapy scale-revised18 and
the cognitive therapy for at risk populations adherence scale19
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to ensure rigorous adherence to the protocol throughout the
duration of the trial. These tapes were drawn from both early
and late phases of therapy and included participants from each
year of recruitment.
Cognitive therapy
Thirteen therapists delivered the cognitive therapy. The number
of participants treated by each ranged between 2 and 35: mean
11 (SD 9). Manchester had five therapists,
Birmingham/Worcestershire and Glasgow each had three, and
Cambridgeshire and Norfolk each had one. Eight were clinical
psychologists (doctoral level) and five were nurses with an
additional specialist qualification in cognitive therapy. All
received additional training associated with the trial manual and
received weekly individual supervision and monthly peer
supervision.
Outcomes
The primary outcome measures were transition to psychosis,
severity of psychotic symptoms, and distress caused by
psychotic symptoms. Each of these was measured using the
CAARMS,15 which provided the data for our primary analyses
examining the effect on time to transition to psychosis, the
reduction in the severity of psychotic symptoms, and the
reduction in distress caused by psychotic symptoms. The
primary endpoint for each of these was 12 months, since
follow-up was planned on all participants to this point.
Transition to psychosis was operationally defined on the
CAARMS using the recommended criteria of a global rating
scale score of 6 on either unusual thought content, non-bizarre
ideas, or disorganised speech, or 5-6 on perceptual
abnormalities, with an associated frequency score of 4-6, and
with these experiences lasting longer than one week. CAARMS
symptom severity was operationalised as the summed scores of
the product of global rating scale score (0-6) and frequency
(0-6) of the four subscales. Distress was operationalised as the
average distress score (0-100) of the four subscales. An
adjudication panel was established to ensure that judgments on
transition were reliable and valid; investigators who were blind
to treatment status (RPB, AIG, SWL, APM, PP) were asked
whether they agreed with the CAARMS ratings of those
participants identified as making transition on the basis of
detailed information from vignettes describing the experiences
of the participants. All such ratings achieved consensus.
Inter-rater reliability of the CAARMS ratings was assessed
regularly (on eight occasions) over the duration of the trial,
using both video and role play assessments, with all trial raters
participating; intraclass correlation coefficients indicated good
reliability between raters: mean 0.90 (SD 0.03). The primary
outcomes were amended to incorporate the non-dichotomous
variables (severity and distress) in addition to transition,
following a decision by the independent data monitoring and
ethics committee, the trial steering committee, and the
representative of the funding body (Medical Research Council);
this was taken at the 18 month point, when it became apparent
that the combined (blinded) transition rate was much lower than
expected (and required by the power calculation).
Secondary outcomes included emotional dysfunction and quality
of life. At baseline and each follow-up, we administered the
global assessment of functioning, the Beck depression inventory
for primary care,20 and the social interactions anxiety scale.21
At baseline and at 6, 12, 18, and 24 months, we additionally
administered the Manchester short assessment of quality of
life.22 The structured clinical interview for the Diagnostic and
Statistical Manual of Mental Disorders, fourth edition
(DSM-IV)23 was used at baseline to determine the presence of
axis I disorders and at exit from the trial to determine any
psychotic diagnoses; we also administered the psychotic
disordersmodule of the structured clinical interview for DSM-IV
if a transition event occurred. These data, in combination with
the case vignettes, were reviewed by two professors of
psychiatry (PBJ, SWL) to establish psychotic diagnoses
(consensus was reached in all but one case, in which consensus
was established with further input from GKM). The social
interactions anxiety scale has a recommended cut-off greater
than 36, indicating a probable diagnosis of social anxiety
disorder,24 and the Beck depression inventory for primary care
has a recommended cut-off greater than 3, indicating a probable
diagnosis of major depressive disorder.20 We recorded
prescriptions of antipsychotic and other psychiatric drugs.
Our earlier trial used a single baseline assessment, and two of
60 participants disclosed after randomisation that they had been
having experiences that met criteria for psychosis. Therefore
our current trial assessed participants for eligibility across two
CAARMS assessments over 2-4 weeks. This ensured, as much
as possible, that we could exclude any individual who was
experiencing or had experienced psychosis.
All participants receive monthly monitoring of mental state for
the first six months after randomisation, as previous studies
have shown that this is the period of maximum risk of transition.
After that, they were monitored every three months up to two
years. Our variable follow-up period meant that participants
recruited in the first 14 months of the study (November
2006-December 2007) were planned to receive the full two year
follow-up. Participants recruited thereafter were offered steadily
reducing follow-up periods, depending on the time of
recruitment. The minimum follow-up period was 12 months.
Sample size
We determined that a two group χ2 test with a 0.05 two sided
significance level would have 80% power to detect the difference
between a 15% transition rate in the cognitive therapy group
and a 30% transition rate in the control group (odds ratio 0.412)
when the sample size in each group was 121. To allow for a
dropout rate of up to 25%, we set our recruitment goal at 320.
We made no allowance for possible therapist effects in these
calculations. These rates of transition were chosen on the basis
of the original small cohort studies and trials, since the more
recent (larger) studies, with lower transition rates, were not
available when funding was sought.
Randomisation and blinding
After the second baseline assessment, participants were
randomised electronically using OpenCDMS.25 The algorithm
uses randomised permuted blocks with block sizes of six or
eight, after stratification by site and sex. OpenCDMS then sent
out email notification of the allocation to the therapists and trial
manager. Thus the results of the randomisation were concealed
from the assessors and randomisation was independent.
Assessors were blind to treatment condition. Many strategies
were used to achieve blind ratings, including research workers
not being involved in the randomisation process, therapists being
required to consider room use and diary arrangements in the
light of potential blind breaks, and patients being reminded by
assessors not to talk about treatment allocation. Overall, 67
blind breaks were reported representing 22.2% of participants.
Therefore blinding was successfully maintained in 77.8% of
participants. Fifteen of these 67 blind breaks were in the
monitoring alone condition and 52 in the cognitive therapy
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condition. In cases where blinding was broken, another rater
assessed the patient for all subsequent assessments or the ratings
were discussed with a blind rater and consensus reached (the
latter was only carried out if there was a clinical justification
not to switch, such as risk considerations or tentative
engagement with the trial). This assessment strategy ensured
that only a few of about 1900 assessments had their validity
threatened by lack of rater blinding.
Statistical analysis
Analysis was agreed with the data monitoring and ethics
committee, and the a priori analysis plan was published.26
Analyses were undertaken in Stata (version 11) after completion
of endpoint assessments. The primary analysis was by intention
to treat.
We analysed transition to psychosis using discrete time survival
models to take into account both the discrete timing of the
follow-up assessments (that is, grouped survival times at three
month intervals) and the random censoring introduced by the
shorter follow-up periods for participants recruited towards the
end of the trial. This involved use of a logistic regression model
that corresponds to Fienberg’s continuation odds model for
grouped survival times.27 Because there were so few events, we
made no allowance for any baseline covariates. Changes in
symptom severity and distress as rated by CAARMS, as well
as secondary outcomes, were analysed using random effects
regression (analysis of covariance) models with summed scores
as dependent variables, allowing for attrition and the variable
follow-up times introduced by the design of the trial. The use
of these models allows the analysis of all available data, on the
assumption that data are missing at random,28 conditional on
adjustment for centre and observed baseline scores. The models
allowed for linear, quadratic, and cubic trends in symptom scores
over time, but only involved testing the treatment by linear trend
interaction—that is, based on the assumption that quadratic and
cubic trends would be the same for both groups. We report
robust standard errors, significance levels, and confidence
intervals. Wemade no adjustments to allow for multiple testing
(using the three primary outcomes, for example).
Results
Recruitment was completed in June 2009. The final sample size
was 288 (80 in Manchester, 77 in Birmingham/Worcestershire,
61 in Glasgow, 30 in Cambridgeshire, and 40 in Norfolk), with
144 patients in each trial arm. Table 3⇓ presents the
characteristics of the whole sample and the baseline balance
across the two groups. Overall, 67% of the sample had at least
one DSM-IV diagnosis at study entry. Specifically, those
meeting DSM-IV diagnostic criteria for emotional disorders at
baseline included 90 with major depressive disorder (33.7%),
20 with dysthymic disorder (7.5%), 17 with panic disorder with
agoraphobia (6.4%), 36 with panic disorder without agoraphobia
(13.5%), 30 with social phobia (11.2%), 29 with specific phobia
(10.9%), 23 with generalised anxiety disorder (8.6%), 20 with
obsessive compulsive disorder (7.5%), and 6with post-traumatic
stress disorder (2.2%). More detailed baseline characteristics
and demographics for the participants are described elsewhere.26
Those allocated to cognitive therapy received a mean of 9.11
(SD 6.69; range 0-26) sessions, each lasting on average one
hour. Adherence to cognitive therapy was reasonably good, with
only 9 of 144 (6.25%) patients not attending any sessions and
108 (75%) receiving at least four or more sessions. Fidelity to
the therapymodel was assessed using competency and adherence
scales in relation to audio recordings of 80 therapy sessions. In
total, 90% of rated sessions scored over the threshold for
competency and 93.3%met the criteria for therapy that adhered
to the manual.
Table 4⇓ shows the time to transition event for each group. Ten
(6.9%) patients who received cognitive therapymade CAARMS
defined transition to psychosis, whereas 13 (9.0%) who received
monitoring alone made CAARMS defined transition to
psychosis. The effect of randomised groups on the odds of an
event (transition) for each of the eight time intervals was tested
simultaneously using a logistic regression model corresponding
to Fienberg’s continuation odds model for grouped survival
times.27 This logistic regression resulted in a non-significant
treatment effect (continuation odds ratio 0.73, 95% confidence
interval 0.32 to 1.68, P=0.45). The DSM-IV diagnoses of those
who made transition were: eight for schizophrenia, five for
schizoaffective disorder, three for delusional disorder, three for
schizophreniform disorder, three for psychotic disorder not
otherwise specified, and one for brief psychotic disorder.
Table 5⇓ shows the results of the primary outcome (CAARMS)
at the 6, 12, and 24 month endpoints. The estimated variables
include a main effect of treatment and a linear effect of treatment
by month interaction. Months of treatment had been centred on
12months (months=0 at 12 months’ follow-up) so that the main
effect of treatment corresponds to the difference between the
two arms determined at 12 months. The treatment by month
interaction indicates how the mean outcomes for two treatment
arms are diverging over time. For severity of psychotic
symptoms, the treatment by time interaction was not significant,
but the difference between treatment arms at 12 months
(cognitive therapy minus control) was estimated to be −3.67
(95% confidence interval −6.71 to −0.64), which was significant
(P=0.018). The negative sign indicates that participants in the
cognitive therapy arm were doing better than the controls. For
distress, the treatment by time interaction was not significant
and the estimated difference at 12 months was −3.03 (−6.95 to
0.94; P=0.14).
Table 5 also shows the results of the secondary outcomes at the
6, 12, and 24 month endpoints. Treatment effects with analysis
of covariance estimates after adjustment for centre and baseline
scores were non-significant for the global assessment of
functioning (estimated difference at 12 months 1.85, −1.34 to
5.05; P=0.26), depression (−0.37, −1.34 to 0.60; P=0.45), social
anxiety (−2.77, −5.98 to 0.45; P=0.09), and quality of life (2.24,
−0.60 to 5.08; P=0.12). Note that these analyses are based on
data from those participants with non-missing baseline covariate
corresponding to the selected outcome. This was a potential
source of bias and lack of precision in the case of theManchester
short assessment of quality of life, which had a lot of missing
measurements at baseline (see table 3). Two simple
modifications were made to the analysis to check whether this
might be the case: dropping the baseline covariate to increase
the sample size from 141 to 190, and using a simple mean
imputation (by site and sex) to replace the missing baseline
values. In both cases the estimated treatment effect at 12 months
decreased to about zero (−0.06 and 0.007, respectively). Table
5 also shows the rates of participants scoring above the threshold
for a likely diagnosis of social anxiety and major depressive
disorders at each time point.
To examine the contribution of the exposure to cognitive
therapy, instrumental variable regression using the adjusted
treatment received algorithm was used to estimate the effects
of number of sessions on 12 month outcomes.29 30 This method
is described in detail in the context of dose-response effects in
psychotherapy trials.31 A regression model was first fitted for
the effects of site and randomised group on sessions, and the
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residuals from this model were saved and used as an additional
covariate in a second regression model for the effects of sessions
on outcome, allowing for site and the baseline value of the
outcome under investigation. This two stage procedure allows
for missing outcomes assuming that they are missing at
random.28 The only significant effect of sessions was found to
be on severity, as assessed by CAARMS (estimated effect at
12 months −0.782 per session, 95% confidence interval −1.329
to −0.234; P=0.005).
Throughout the duration of the trial 14 participants in the
cognitive therapy armwere prescribed antipsychotics compared
with 13 in the monitoring alone arm.
Discussion
Although cognitive therapy for young people (aged 14-35)
meeting the criteria for being in an at risk mental state did not
affect transition to psychosis over 12-24 months, it significantly
reduced the frequency and intensity of psychotic experiences.
Cognitive therapy did not significantly affect distress related to
these psychotic experiences as measured by the CAARMS, nor
levels of depression, social anxiety, or satisfaction with life.
Comparison with other studies
This is the first multisite randomised controlled trial of cognitive
therapy for people in an at risk mental state and the largest
randomised controlled trial of this population to date. The results
are consistent with findings from clinical trials on people in an
at risk mental state. Most trials found that severity of psychotic
experiences could be reduced over a moderate timeframe,2 4 6 8
such as 12 months, whereas some found that it was not possible
to reduce transition to psychosis over such a period.2 4 5 The
exceptions to this were our earlier single site trial and an
Austrian trial involving polyunsaturated fatty acids, both of
which found a reduction in transition rate at 12 months. These
trials were, however, smaller than the present one, which may
have led to a type 1 error. A reduction in severity of psychotic
symptoms is clearly desirable in young people at risk. The lack
of an effect on transition to psychosis is, however, disappointing.
In our trial the low rates of transition (6.9% for cognitive therapy
and 9.0% for monitoring) are consistent with the declining rates
of transition observed in populations in an at risk mental state,
which were commented on recently,32 especially those found in
clinical trials (table 1). Our transition rate for cognitive therapy
was almost the same as that in our original trial (6%), although
the low rate observed in the control condition brings into
question how “at risk” such patients were, and also means that
our trial was significantly under-powered to detect a difference
in these observed conversion rates. Although we failed to show
a statistically significant effect of the intervention we cannot
rule out a beneficial effect of the cognitive therapy on transition
rate (although it could be argued that the sample size required
to show such an effect, and the small effect sizes reported here,
would make such an endeavour unfeasible in practical terms
and unwarranted in clinical terms). Our secondary outcomes
did not show any benefit from active treatment, although anxiety
and depression noticeably decreased over time in both groups,
suggesting a natural recovery process in operation. Similarly,
satisfaction with life improved for both groups over time. It
may be possible to affect such outcomes directly with a more
targeted intervention that specifically aims to improve
depression and social anxiety.
Given that the significant effects on severity resulted in an
estimated difference of about 4 points on our scale (an
interaction of frequency and intensity, each of which are 0-6),
this represents a clinically meaningful improvement (for
example, changing from an intensity rating of severe tomoderate
or moderately severe to mild, with an accompanying change in
frequency from daily or several times a day to less than twice
a week). Each session was associated with about a 1 point
difference in severity, which itself is of less clinical significance,
but an accumulation of sessions will lead to clinically significant
change.
Strengths and limitations of the study
Our trial shows methodological rigour in several ways. Large
trial sample sizes generally produce smaller effects, and ours is
the largest trial to date with a population in an at risk mental
state. Our findings, therefore, follow the trend observed in trials
of specific psychological therapies, such as cognitive therapy,
which have shown that effect sizes are decreased when indices
of study quality (such as adequate statistical power and a control
condition that is more active than treatment as usual) are
controlled for, within cognitive therapy for both depression33
and psychosis.34 Importantly, we prespecified the primary and
secondary outcomes to be analysed, reducing the likelihood of
type 1 errors. The use of five sites should ensure generalisability
to routine clinical service provision. However, there are some
potential difficulties with our trial. The significant finding of a
reduction in severity of psychotic experiences as a result of
cognitive therapy would become of borderline significance if
we were to adjust for multiple testing using a Bonferroni
correction (there being three primary outcomes). We excluded
29 participants who had reported meeting the criteria for being
in an at risk mental state at first baseline assessment but reported
psychotic experiences consistent with transition at the second
baseline assessment. This was a cautiousmanoeuvre to eliminate
the possibility that such individuals were under-reporting at
baseline and were, therefore, appropriately excluded on the basis
of psychosis at first baseline assessment. Alternatively, they
could have been incorrectly excluded (that is, were genuinely
at risk at first baseline assessment and developed psychosis in
the intervening period). If so, we may have excluded those
participants at highest risk of immediate transition, which would
adversely affect the statistical power of the trial. The inclusion
of these 29 would have given an overall transition rate of 18%,
which is similar to that found in the recent cohort studies. A
significant proportion of the data was missing, which also may
introduce the possibility of bias. As the proportions were similar
for both groups we attempted to identify whether people had
made transition to psychosis when lost to follow-up by way of
reports from family doctors of contact with services and
prescription of antipsychotics. This showed that only one
participant seemed to have made transition, who had been
allocated to the monitoring only condition. We did not measure
exposure to treatment before study entry (except for
antipsychotic drugs), so we are unable to allow for this in our
analyses. Given the lower than expected transition rates, our
sample used CAARMS criteria with a 30% reduction in global
assessment of functioning score for the family history group
only; subsequent versions of the CAARMS have applied a 30%
reduction in global assessment of functioning score for all
groups.
Conclusions and implications
The reduced transition rate as well as the natural course of
recovery that was observed for many of the participants in both
conditions, is of considerable interest, and could be due to our
sampling approach, the effectiveness of an active control
condition, or the lack of validity of the concept of being in an
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at risk mental state. It is possible that the need to actively recruit
to target using ascertainment strategies in such diverse settings,
modified the “risk enriched” status of the sample such that we
included people with a lower risk of transition.35 However, our
recruitment strategy was similar to that in most of the other
trials, our entry routes were equivalent to other trials
(predominantly through the attenuated symptoms pathway), and
our baseline levels of psychotic experiences and functioning
(for example, global assessment of functioning scores) were
also similar to those of the other trials. It is likely that the active
monitoring control included therapeutic aspects (supportive
listening, access to crisis care, signposting), which were more
beneficial than envisaged, consistent with the suggestion that
benign and simple interventions are effective earlier in the
emergence of psychotic disorders, implicit within the concept
of a clinical staging model.36 It is also possible that the
discrepancies in transition rates between the clinical trials with
active control conditions (range 0-22% over 12 months, table
1) and the large recent cohort studies37 38 (range 14-22% over
12 months) may be influenced by factors such as participation
in a trial and the strength of therapeutic benefits of active control
conditions. This would be consistent with the high engagement
rates and low dropout rates found in the trials with psychosocial
interventions (table 1).
Our observations also suggest that a review of the “ultra high
risk” strategy, in particular the influence of community
ascertainment strategies on risk or protective factors for
psychosis and of natural recovery processes in adolescence and
early adulthood, is required. In relation to the recovery in early
adulthood, epidemiological studies of psychotic-like experiences
suggest an increase and decrease in such experiences in late
adolescence,39 40whichmay impinge on ascertainment strategies
for at risk mental states, especially given that about 80% of such
participants meet the criteria on the basis of such attenuated
symptoms. Even in the recent cohort studies, the 12 month
transition rates were considerably lower than the 50% at 12
months from the original progenitor cohort study.1 Taken
together, these findings have important implications for the
proposal to incorporate a psychosis risk syndrome in DSM-V,
raising questions about its utility as a predictive concept and
also about the likely cost-benefit ratio of providing treatment
for this group.41
The at risk mental state paradigm has been of great benefit in
developing thinking about prevention, but these data suggest it
needs further research and refinement, particularly in light of
the findings on the declining transition rates and their link with
community sampling strategies that are required to obtain large
samples. The natural ebb and flow of psychotic experiences and
co-occurring affective symptoms within adolescence,39 40 as well
as the findings that psychotic experiences are often reported by
patients with both affective and anxiety disorders42 and that the
persistence of psychotic experiences is linked with increased
levels of affective symptoms,43 have led to suggestions that
depression and anxiety should be considered as necessary
conditions for the onset of psychosis.44 If the criteria for at risk
mental state were revised to incorporate such affective
disturbances, this could identify a higher risk sample; this is in
keeping with the findings of recent cohort studies that have
examined predictors of transition.37 38 The affective disturbances
within our population may trigger help seeking behaviour but
it may also be that increasing emotional dysregulation is
intrinsically linked to the acceleration of psychotic experiences,
possibly through negative appraisal (as threat related or loss
related), and would, therefore, predict transition to or an increase
in severity of psychosis. This requires further research on the
process of transition to psychosis itself. If this turns out to be
the case, then simple and benign interventions that target
affective disturbances (such as behavioural activation, short
term cognitive therapy, interpersonal psychotherapy, and
antidepressant or anxiolytic drugs), together with a focus on
how clients appraise these experiences and regulate affect, could
offer a more powerful method of reducing distress and transition.
This would be in keeping with the findings in our trial, since it
is clear that both groups improved significantly in terms of
psychotic experiences, distress, anxiety, and depression. It is
also possible that the therapeutic effects of our monitoring
control were greater than expected, since it provided regular
contact with non-judgmental, warm, empathic, and accepting
individuals who provided a non-stigmatising,
non-catastrophising reaction to disclosures of unusual
experiences and beliefs, which may have been beneficial. This
would also be consistent with recent findings that brief,
relatively simple, psychological interventions that target anxiety
processes (worry) have a significant effect on psychotic
experiences (persecutory ideation) in people with psychosis.45
In summary, it is important that future research examines the
developmental processes involved in both transition to psychosis
and resilience within populations in an at risk mental state, but
it seems highly premature to introduce a diagnostic category
into DSM-V on the basis of risk of psychosis, given the low
transition rate and high potential for natural recovery. This
population is clearly help seeking and distressed, with the
majority meeting criteria for a diagnosable emotional
disorder.46 47 Therefore, future clinical trials should consider
provision of problem led, benign, and parsimonious
interventions that target presenting difficulties (be they anxiety
disorders, depression, or distressing attenuated psychotic
experiences) rather than prevention of transition to first episode
psychosis in itself.
This study has several clinical implications. Cognitive therapy
reduces the severity of psychotic experiences without the use
of antipsychotic drugs, which should provide the benefits of
symptom based improvement without the associated risks of
serious side effects. However, the low rate of transition to
psychosis in both groups and the recovery from psychosis and
affective symptoms is clearly an important and optimistic
message to convey; both for young help seeking people meeting
the criteria for being in an at risk mental state and for clinicians
in contact with this population. It should encourage a
normalising, non-catastrophic perspective on their psychotic
experiences, and any treatment should largely be needs driven
on the basis of what problems are presented and prioritised by
service users; this is something that cognitive therapy is suited
to, given its collaborative, problem oriented nature. However,
active monitoring may also be beneficial and would be benign,
easy to implement, and consistent with guidelines from the
International Early Psychosis Association on treatment in the
at risk phase48; a period of watchful waiting involving regular
monitoring that lasts for at least 12 months could be safely
recommended. The ethics of intervening before the onset of a
disorder are always debatable, and this is especially so in relation
to the use of antipsychotics for people in an at risk mental state,
which often have significant adverse effects; for example, a
recent systematic review concluded that some of the structural
abnormalities in brain volume that have previously been
attributed to the syndrome of schizophrenia may be the result
of antipsychotic drugs,49 which has been recently supported by
a high quality prospective study50 as well as experimental studies
in healthy volunteers.51 There is also evidence that increased
cardiovascular risk is detectable after first exposure to any
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antipsychotic drug52 and there is overwhelming evidence of
weight gain induced by antipsychotics.53 On the basis of low
transition rates, high responsiveness to simple interventions
such as monitoring, a specific effect of cognitive therapy on the
severity of psychotic symptoms, and the toxicity associated with
antipsychotic drugs, we would suggest that antipsychotics are
not delivered as a first line treatment to people meeting the
criteria for being in an at risk mental state.
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What is already known on this topic
It seems possible to identify a population at ultra high risk of developing psychosis
Several small trials suggest promising interventions for the prevention of psychosis and improvement in psychotic symptoms in these
populations
What this study adds
Cognitive therapy did not prevent transition to psychosis but did reduce the severity of psychotic symptoms in young people (aged 14-35)
at risk of psychosis
The rates of transition are lower than previously thought and there is a high potential for recovery with minimal intervention in this
population
It is important to reconsider whether young people meeting these criteria can be accurately described as being at “ultra high risk of
psychosis”
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Tables
Table 1| Summary of clinical trials on at risk mental state
Dropout rates
(%)Outcomes
Transition rates
(%)
Intervention/follow-up
periodsIntervention groups
Age
range
No (%
male)Study
42 from
antipsychotic
drugs+cognitive
behaviour
therapy
Significant difference in transition
rate at 6 months but not at 12
months. Both groups improved on
symptoms, but no difference
between groups. No differences at
48 months
10 v 36 at 6
months; 19 v 36
at 12 months
6 months’ intervention;
12 months’ follow-up; 48
months’ follow-up54
Antipsychotic
drugs+cognitive behaviour
therapy v needs based
intervention
14-3059 (58)McGorry et al
(2002)2 54
13.5 from
cognitive
behaviour
therapy
Significant difference in transition
rate (using all three definitions) and
symptoms at 12 months; only
difference at 36 months was in
prescription of antipsychotic drugs
6 v 22-30 at 12
months
6 months’ intervention;
12 months’ follow-up; 36
months’ follow-up7
Cognitive behaviour therapy
v monthly monitoring plus
treatment as usual
14-3658 (69)Morrison et al
(2004)6 7
54.8 v 34.5No significant difference in transition
rates at 12 or 24 months. Significant
difference in symptoms at 12
months in favour of antipsychotic
drugs
16.1 v 37.9 at 12
months
12 months’ intervention;
24 months’ follow-up
Antipsychotic drugs v
placebo
12-3660 (65)McGlashan et
al (2006)4
7.3 v 5Significant differences in transition
rate and symptoms at 12 months in
favour of polyunsaturated fatty acids
4.0 v 27.5 at 12
months
3 months’ intervention;
12 months’ follow-up
Polyunsaturated fatty
acids+needs based
psychological intervention v
placebo+needs based
psychological intervention
13-2581 (34)Amminger et
al (2010)8
29.6 v 20.8No significant difference in transition
rates. Both groups improved on
symptoms, but no difference
between groups
0 v 12.5 at 6
months
6 months’ intervention;
18 months’ follow-up
Cognitive behaviour therapy
v supportive psychotherapy
14-3051 (71)Addington et
al (2011)5
16 v 20 v 21No significant difference in transition
rates; all groups improved on
primary symptom measure (interim
analysis)
4.7 v 9.1 v 7.1 at
6 months
(interim)
12 months’ intervention
(6 months’ interim
analysis)
Cognitive behaviour
therapy+antipsychotic drugs
v cognitive behaviour
therapy+placebo v
supportive
psychotherapy+placebo
14-30115 (39)Yung et al
(2011)3
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Table 2| Referral sources for participants
No (%)Referral source
97 (33.6)Early intervention for psychosis service
32 (11.1)General practitioner
28 (9.7)Primary care mental health team
24 (8.3)Youth counselling service
22 (7.6)Secondary care community mental health team
19 (6.6)University counselling service
16 (4.6)Housing or homeless services
15 (5.2)Child and adolescent mental health services
11 (3.8)Substance misuse services
6 (2.1)Self referral
5 (1.7)Acute psychiatric inpatient unit
4 (1.4)Youth offending team
3 (1.0)Secondary care crisis and home treatment team
2 (0.7)Family member or carer
4 (1.4)Other
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Table 3| Baseline characteristics of participants. Values are means (standard deviations) unless stated otherwise
Monitoring only (n=144)Cognitive therapy plus monitoring (n=144)Whole sample (n=288)Characteristics
20.75 (4.50), n=14420.73 (4.18), n=14420.74 (4.34), n=288Age
91:5389:55180:108Male:female
38.15 (17.80), n=14338.72 (16.84), n=14338.44 (17.30), n=286CAARMS severity (summed, 0-144)
42.45 (19.62), n=13442.77 (20.51), n=13042.61 (20.03), n=264CAARMS distress (average, 0-100)
51.15 (10.25), n=14450.98 (10.98), n=14451.06 (10.60), n=288Global assessment of functioning
9.02 (4.70), n=12710.41 (4.15), n=1319.73 (4.48), n=258Beck depression inventory-primary care total
107/127 (84)122/131 (93)229/258 (89)No (%) above Beck depression inventory threshold
39.36 (16.93), n=11342.88 (16.92), n=12141.18 (16.98), n=234Social interaction anxiety scale total
65/113 (58)76/121 (63)141/234 (60)No (%) above social interaction anxiety scale threshold
49.10 (11.00), n=9646.33 (9.60), n=9947.70 (10.10), n=195MANSA total
CAARMS=comprehensive assessment of at risk mental state; MANSA=Manchester short assessment of quality of life.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:e2233 doi: 10.1136/bmj.e2233 (Published 5 April 2012) Page 11 of 14
RESEARCH
Table 4| Number of transitions to psychosis in each group (and cumulative total) at each assessment occasion and maximum number
available at each occasion (owing to variable follow-up design)
Month of assessment
Group 24211815129654321
1 (13)1 (12)1 (11)0 (10)1 (10)3 (9)0 (6)1 (6)2 (5)0 (3)2 (3)1Monitoring (cumulative total)
2 (10)0 (8)1 (8)0 (7)0 (7)1 (7)0 (6)1 (6)1 (5)1 (4)1 (3)2Cognitive therapy (cumulative total)
164195224251288288288288288288288288Maximum No
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Table 5| Results of primary and secondary outcome variables at 6, 12, and 24 months. Values are means (standard deviations) unless
stated otherwise
24 months12 months6 months
Variable Monitoring onlyCognitive therapyMonitoring onlyCognitive therapyMonitoring onlyCognitive therapy
CAARMS:
18.84 (20.52), n=3113.94 (16.07), n=3420.84 (17.75), n=9314.88 (15.54), n=9518.69 (19.34), n=9917.89 (16.50), n=97Severity
17.72 (21.31), n=2912.82 (16.56), n=3319.49 (18.26), n=9114.72 (16.87), n=9217.84 (19.43), n=9718.33 (20.67), n=91Distress
60.19 (16.88), n=3164.12 (17.71), n=3458.59 (16.23), n=9460.74 (16.69), n=9561.61 (15.04), n=9859.30 (16.21), n=97Global assessment of functioning
Beck depression inventory-primary
care:
6.00 (4.77), n=284.85 (4.49), n=335.72 (4.92), n=905.41 (5.12), n=935.61 (4.79), n=935.60 (4.72), n=92Total score
15 (54)19 (58)55 (61)51 (55)55 (59)56 (61)No (%) with score >3
Social interaction anxiety scale:
36.42 (19.48), n=2627.81 (17.30), n=3229.99 (16.60), n=8732.51 (17.08), n=9130.60 (16.91), n=9030.85 (17.98), n=82Total score
11 (42)9 (28)32 (37)37 (41)36 (40)30 (37)No (%) with score >36
52.33 (11.32), n=2156.78 (10.55), n=2754.65 (11.75), n=6853.38 (12.60), n=6653.00 (11.45), n=6653.17 (12.38), n=75MANSA
CAARMS=comprehensive assessment of at risk mental states; MANSA=Manchester short assessment of quality of life.
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Figure
Flow of participants through study
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